MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/ijgm.s515389

Медицинская библиотека · International journal of general medicine · 2025

Impact of Treatment Interruption on the Effectiveness of Interleukin (IL)-17A Inhibitors in Plaque Psoriasis: A Retrospective Analysis.

Jiang Jin, Zhang Meihua, Li Mi

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Plaque psoriasis is a chronic, recurrent, immune-mediated inflammatory skin disease. This study aimed to investigate effectiveness of interleukin (IL)-17A inhibitor treatment and effectiveness after treatment interruption in plaque psoriasis patients and analyze the related factors.

METHODS

This study retrospectively collected clinical characteristics and related treatment status of plaque psoriasis patients treated with IL-17A inhibitors, and evaluated the treatment effectiveness, reasons for treatment interruption, effectiveness after treatment interruption, and risk factors affecting treatment effectiveness.

RESULTS

This study ultimately included 106 patients with plaque psoriasis, including 61 males (57.55%) and 45 females (42.45%), aged 41.0 (31.0-54.0) years and with a disease duration of 12.0 (8.0-20.0) months. Among them, 71 cases (67%) achieved PASI90 after receiving IL-17A inhibitor treatment, and 35 cases (33.02%) achieved PASI75. A total of 50 patients (50/106, 47.17%) interrupted treatment, 23 patients (23/50, 46%) maintained a therapeutic effect of PASI90 or above, and 27 patients (27/50, 54%) had a therapeutic effect lower than PASI75, with median time of treatment interruption of 1.0 (1.0-3.5) months. Univariate analysis findings showed that duration of IL-17A inhibitor treatment interruption and reasons for interruption had significant statistical significance on treatment effectiveness (all P<0.05). In multivariate analysis, treatment interruption (OR=7.154, 95% CI: 2.528-20.24) and reasons such as stress/anxiety (OR: 14.889, 95% CI: 1.160-23.480) were risk factors affecting treatment effectiveness.

CONCLUSION

Interleukin (IL)-17A inhibitor treatment interruption plays critical effects on the treatment of plaque psoriasis. Early and long-term adherence to IL-17A inhibitor treatment can control the course of the disease and improve the long-term health of psoriasis patients.

Для цитирования: Jiang Jin, Zhang Meihua, Li Mi. Impact of Treatment Interruption on the Effectiveness of Interleukin (IL)-17A Inhibitors in Plaque Psoriasis: A Retrospective Analysis.. International journal of general medicine. 2025. DOI: 10.2147/ijgm.s515389.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.